Recent advances in molecular biology of thyroid cancer and their clinical implications.
about
The positive clinical therapeutically effects of Escin on advanced thyroid cancer.Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.New insights into the diagnosis of nodular goiter.Molecular pathogenesis and mechanisms of thyroid cancerIQGAP1 plays an important role in the invasiveness of thyroid cancerMethylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signalingCorrelation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinomaStandard and emerging therapies for metastatic differentiated thyroid cancer.The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cellsBeneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.Association between the KRAS Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population.Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer TreatmentsThe significance of epigenetic alterations in lung carcinogenesis.New insight into the treatment of advanced differentiated thyroid cancer.Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse modelGenetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.The mTOR protein as a target in thyroid cancer.Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.BRAFV600E mutation and papillary thyroid cancer: chicken or egg?Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.
P2860
Q33679565-6B376944-AEE6-44A2-A5F1-CA88F8CE68FBQ33736109-342A43D1-851E-49B5-A901-7BD2C7F3A88BQ33827492-92253A00-7E12-4B34-B8B0-D561463668D6Q34329018-167529C3-A628-4D18-AD1B-CDF0489A2D8EQ34420079-BC4EA819-6324-4409-8313-16C3D9B250FCQ34466347-F2BD340E-1D9E-40BB-9653-BAB970965CEAQ34588501-EF2CA91A-D38B-4175-9261-4E7586ED1498Q35583906-C703389C-76CC-4750-80CC-8DE1592E5ED6Q35744471-79FB28ED-0D67-4BF7-8115-D431D1BBFD08Q35941777-BC7C67BF-B4F9-4201-BA08-54977A2A3360Q35969385-2BFA0C83-E3C8-4B9A-B047-E4B87767D820Q36229033-8A5B1F21-87D2-49A9-B615-F160AB4EACC2Q36366960-96C8CBAD-B77D-4E79-9D2F-ECE7A9AFB591Q36457427-2CEE901B-BB3A-4965-AF3D-0AE895D8CD72Q36528466-7E539820-FAA8-4EC7-9326-C8514E398DFFQ36905783-5DE8243C-12EB-4DA9-B030-F66E90354753Q37205853-A5437977-9FA8-48B2-838B-E4C220AD1DAFQ37373348-42D0D2BC-7772-45CC-84E7-8252469FC482Q37767709-EE1F9AC8-701D-41CB-9AED-E161E89E27FFQ37894106-FF11CE6B-9463-4C2F-BDF6-81ECE59FBD3AQ38630967-02EADC5E-0027-46CB-BC88-11C697BAC7A5Q38644584-31006C1D-16C1-4309-A4A3-4119C5DBDBA8Q38995525-03BC2387-FA90-4F2D-A085-C88B6335432EQ38995628-FA06AE7A-9174-4324-9B39-40432C739179Q39326839-C817C5D5-B3D6-4471-95E1-4C84092C4409Q39586177-A7FCE73F-CB56-435B-8221-CA34C9D79BABQ39588375-93B20150-257E-4257-8948-986208883788Q39842295-DB8CC4C6-AED5-441A-9520-1A8A1765E89AQ42707282-1419C7A1-7AAA-4ADA-8326-3EFBD59E0B44Q42950764-3209558E-4F99-4FCB-9CF4-A78DC0F32849
P2860
Recent advances in molecular biology of thyroid cancer and their clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@en
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@nl
type
label
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@en
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@nl
prefLabel
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@en
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@nl
P2860
P1476
Recent advances in molecular biology of thyroid cancer and their clinical implications.
@en
P2093
Mingzhao Xing
P2860
P304
1135-46, ix
P356
10.1016/J.OTC.2008.07.001
P577
2008-12-01T00:00:00Z